Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04164212 · ClinicalTrials.gov registry record · Phase 4
Live Attenuated Influenza Vaccine as a Nasal Model for Influenza Infection
A Phase 4 study, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- Phase 4
- Development phase
- 33
- Enrollment target
NCT04164212 is a Phase 4 study that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 33 participants.
The verdict
NCT04164212, a Phase 4 study, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 33 participants
- Enrollment target
Study Summary
The purpose of this study is to develop a nasal model for influenza infection using the live attenuated influenza vaccine (LAIV). The investigators will administer LAIV to healthy adult volunteers in order to simulate influenza infection, and obtain nasal specimens to measure influenza virus and inflammatory/immune responses. In a subset of participants, cystic fibrosis transmembrane conductance regulator (CFTR) function will also be evaluated via measurement of nasal potential difference (NPD)
Interventions
- DRUG Flumist Quadrivalent Nasal Product
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2020-09-01 |
| Est. Completion | 2026-01-22 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04164212
The ClinicalTrials.gov registry entry for NCT04164212 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Flumist Quadrivalent Nasal Product is the first listed.
NCT04164212 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04164212 about?
NCT04164212 is a clinical study titled "Live Attenuated Influenza Vaccine as a Nasal Model for Influenza Infection". The purpose of this study is to develop a nasal model for influenza infection using the live attenuated influenza vaccine (LAIV). The investigators will administer LAIV to healthy adult volunteers in order to simulate influenza infection, and obtain nasal specimens to measure influenza virus and inf...
What is the current status of trial NCT04164212?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 33 participants. The study started on 2020-09-01. Estimated completion is 2026-01-22.
What interventions are being tested in trial NCT04164212?
The interventions under investigation include: Flumist Quadrivalent Nasal Product (DRUG).
Who is sponsoring clinical trial NCT04164212?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.